Rhofade

Rhofade (oxymetazoline hydrochloride cream, 1%) is a prescription topical treatment for persistent facial redness associated with rosacea, developed by Allergan (now part of AbbVie). It is not a telehealth platform itself but surfaces in AI-generated answers about online dermatology, currently ranking 12th in that category with 8% visibility in the WellRank index, and the one mention captured in the WellRank corpus carries a positive tone.

Rhofade is a branded prescription medication rather than a standalone company. It is manufactured and marketed by AbbVie following its acquisition of Allergan. The product is distributed through traditional pharmacy channels and increasingly discussed in the context of telehealth prescribing workflows, where online dermatology platforms can evaluate and prescribe it remotely.

• Oxymetazoline hydrochloride cream 1%, an FDA-approved topical alpha-1A adrenoceptor agonist
• Once-daily application formulated specifically for facial erythema of rosacea
• Targeted vasoconstriction mechanism to reduce visible redness without oral systemic exposure
• Supplied as a topical cream intended for use on the face only
• Available by prescription, accessible via both in-person dermatologists and telehealth providers

Rhofade is indicated for adults with persistent facial erythema associated with rosacea. It is primarily relevant to patients in the United States, where it holds FDA approval. The typical candidate is an adult seeking visible redness reduction rather than treatment of rosacea papules or pustules.

• An adult with moderate to severe rosacea-related facial redness who wants a fast-acting topical option without oral medication.
• A telehealth patient consulting an online dermatology service who needs a prescription-strength alternative to cosmetic concealers.
• A rosacea sufferer who has already tried over-the-counter products and is researching prescription treatments through AI-assisted health searches.
• A dermatology patient transitioning from a similar alpha-agonist like Mirvaso and looking for a tolerability comparison.

Rhofade is a commercial prescription product owned by AbbVie, a publicly traded pharmaceutical company. Revenue figures specific to Rhofade are not publicly disclosed as a separate line item in AbbVie's financial reporting.

Rhofade continues to be prescribed through expanding telehealth dermatology channels, reflecting broader industry growth in online prescription skincare. AbbVie has maintained the product in its dermatology portfolio following the Allergan acquisition, though specific promotional campaigns or formulation updates are not publicly detailed at this time.

The WellRank corpus records one AI mention of Rhofade to date, and that mention is positive in tone, with no neutral or cautious characterizations logged. Broader public sentiment, as reflected in patient reviews on health forums, tends to focus on its speed of visible redness reduction, though some users note cost and insurance coverage as friction points.

Rhofade is a branded prescription product and its retail price varies by pharmacy, insurance coverage, and any manufacturer savings programs in effect. Exact out-of-pocket figures are not published in a stable way; patients are generally advised to check with their pharmacy or use a drug pricing tool, as costs without insurance can be substantial for branded topicals.